UK-based Synairgen, which is developing SNG001 inhaled interferon-beta-1a, announced that former Chiesi Global Head of Drug Development Mark Parry-Billings will succeed Simon Shaw as Chairman of the Board. Shaw will retire in October 2024. Prior to joining Chiesi in 2011, Parry-Billings was CEO of Topigen Pharmaceuticals, which was sold to Pharmaxis in 2010. His previous experience included stints at pSivida and Innovata Biomed, which was later acquired by Vectura.
Simon Shaw, Chairman of the Board of Synairgen, said: “I am delighted to hand over the reins to Mark, who is a world class inhaled drug development leader. Synairgen now has both a rigorous development plan for SNG001 and someone with the optimal experience to guide the company’s direction through this next phase.”
Mark Parry-Billings said: “I have followed Synairgen’s approach to SNG001 as a potential broad-spectrum antiviral for a wide range of severe lung infections for some time and look forward to working with the Board and broader team on its clinical development in a crucial area of unmet need, whilst acknowledging Simon’s highly effective leadership of the Board to date.”
Read the Synairgen press release.
